Market Reports Center One Stop Market Reaserch Shop Biosimilars Market Share, Size, Emerging Trends and Growth, Analysis, Overview and Forecasts 2016-2020 Technavio Announces the Publication of its Research Report – Global Biosimilars Market 2016-2020 Technavio recognizes the following companies as the key players in the global biosimilars market: Sandoz, Hospira, Teva Pharmaceuticals, STADA, Biocon, Celltrion, Dr. Reddy's, Other Prominent Vendors in the market are: 3SBio, Accord Healthcare, AET Biotech, Allergan, Alvartis Pharma, Amega Biotech, Amgen, Apotex, Aspen, AstraZeneca, Aurobindo Pharma, Baxter, Bharat Serums, Bio Sidus, Biogen, Bionovis, Bioton, BioXpress Therapeutics, Boehringer Ingelheim, Boston Oncology, Cipla, Coherus Biosciences, Daiichi Sankyo, Emcure Pharmaceuticals, Gedeon Richter, GeneScience Pharmaceuticals, GSK, Hetero Drugs, iBio, Intas Pharmaceuticals, JCR Pharmaceuticals, LG Lifesciences, Lonza, Merck, Mitsubishi Tanabe Pharma, Momenta Pharmaceuticals, Mylan, Mylan, Mylan, Pfenex, Pfenex, Ranbaxy Laboratories, Roche Holding, Samsung Biologics, Sanofi, Synthon, Wockhardt, and Wockhardt. Browse full report with TOC@ https://marketreportscenter.com/reports/349501/global-biosimilarsmarket-2016-2020 Commenting on the report, an analyst from Technavio’ s team said: “Emergence of biosimilars will be a key trend for market growth. The sales of biologics are expected to decline during the forecast period, owing to the increased sales of their biosimilar versions, which cost lesser and are almost similar to their originator biologic compounds. For instance, epoetin alfa BS injection by JCR Pharmaceuticals and Kissei Pharmaceutical is a biosimilar form of epoetin alfa that was launched in the market in May 2010. Similarly, the US FDA approved Inflectra in April 2016 to treat autoimmune and inflammatory diseases.” Market Reports Center One Stop Market Reaserch Shop According to the report, Reimbursement benefits for biosimilars will be a key driver for market growth. Lack of cost-effectiveness impeding the coverage of drugs results in variations in the reimbursement status of drugs from region to region. The Medicare and Medicaid reimbursement plans are expected to have an impact on the global scenario for diseases such as diabetes, which have high prevalence and incidence rates in the US. Medicare provides coverage for the older population (65 years or older), people with the end-stage renal disease (ESRD), and people aged below 65 years with certain disabilities. Further, the report states that the reluctant nature of physicians to prescribe biosimilars will be a challenge for the market. Physicians are reluctant to prescribe biosimilars to patients, as biologics cannot be substituted with these drugs. Biologics are developed using a living system or a genetically modified organism. A slight variation in the manufacturing process, in terms of conditions and the formulation of biosimilar products can affect the safety and efficacy of the final product. Biosimilars can also not be used during post-marketing surveillance as the substitution of drugs is prohibited in a country during this period. Also, similar to generic drugs, physicians do not receive financial incentives for prescribing biosimilars. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Request A Sample copy of This Report @ https://marketreportscenter.com/request-sample/349501 About Biosimilars Biosimilars are defined as the follow-on versions of original biological medicines. These are separately developed after the patent protecting the original product has expired. Biosimilars are intended to have the same MOA as original biological drugs and are designed to treat the same diseases as the innovator’ s product. They have many similarities, but are not identical to, the reference biopharmaceutical product. Technavio’ s analysts forecast the global biosimilars market to grow at a CAGR of 55.52% during the period 2016-2020. Covered in this report The report covers the present scenario and the growth prospects of the global biosimilars market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sale of products such as somatropin, erythropoietin, colony-stimulating factors (CSF), interferons, interleukins, insulin and insulin analogs, follicle stimulating hormones (FSH), monoclonal antibodies (mAbs), and low molecular weight heparins (LMWH). Market Reports Center One Stop Market Reaserch Shop The market is divided into the following segments based on geography: • Americas • APAC • EMEA Technavio's report, Global Biosimilars Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. To Get Discount On The Report @ https://marketreportscenter.com/request-discount/349501 Connect for more details: Sam Collins Market Reports Center 1-646-883-3044 (US) info@marketreportscenter.com

According to the report, Reimbursement benefits for biosimilars will be a key driver for market growth. Lack of cost-effectiveness impeding the coverage of drugs results in variations in the reimbursement status of drugs from region to region.